<DOC>
	<DOCNO>NCT00242385</DOCNO>
	<brief_summary>The primary purpose study characterize pharmacokinetic profile intravenous Aralast Fraction ( Fr . ) IV-1 , sterile , stable , lyophilized preparation functionally intact human Alpha1- Proteinase Inhibitor ( α1-PI ) . This pharmacokinetic study randomize controlled clinical trial cross-over design . Twenty-four subject enrol study . Overall study duration approximately 6-8 month .</brief_summary>
	<brief_title>Pharmacokinetic Study ARALAST ( Human Alpha1- PI )</brief_title>
	<detailed_description />
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>The subject subject´s legally authorize representative provide write informed consent Subject 18 year age old Subject document , endogenous plasma Alpha1PI level &lt; 8 Micromolar Subject genotype Pi*Z/Z , Pi*Z/Null , Pi*Null/Null , Pi*Malton/Z , others , dependent approval Sponsor If subject female childbearing potential , subject negative urine test pregnancy within 7 day prior first study product administration agree employ adequate birth control measure duration study Laboratory result obtain screen visit , meet follow criterion : Serum alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &lt; = 2 time upper limit normal ( ULN ) Serum total bilirubin &lt; = 2 time ULN Proteinuria &lt; +2 dipstick analysis Serum creatinine &lt; = 1.5 time ULN Absolute neutrophil count ( ANC ) &gt; = 1500 cells/mm3 Hemoglobin &gt; = 10.0 g/dL Platelet count &gt; = 10^5/mm3 If subject treat respiratory medication , include inhaled bronchodilator inhale oral corticosteroid , subjects´ medication dos unchanged least 14 day prior first study product administration Nonsmoker minimum 3 month prior first study product administration The subject receive Alpha1PI augmentation therapy ( include Aralast investigational Alpha1PIs , route include intravenous inhale ) within 42 day prior first study product administration The subject receive investigational drug device within 1 month prior first study product administration , subject currently receive investigational drug The subject know selective immunoglobulin A ( IgA ) deficiency ( IgA level &lt; 15 mg/dL ) and/or antibody IgA The subject pulmonary exacerbation pulmonary exacerbation past 14 day prior first study product administration The subject pregnant lactating , intend become pregnant course study The subject clinically significant medical , psychiatric , cognitive illness , recreational drug/alcohol use , opinion investigator , would affect subject safety compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Severe congenital Alpha1-Proteinase Inhibitor ( Alpha1-PI ) deficiency</keyword>
</DOC>